Dicerna doses first volunteer in Phase 1 clinical trial of DCR-HBVS
Dicerna Pharmaceuticals announced the dosing of the first human volunteer in its Phase 1 clinical trial of DCR-HBVS, the Company's investigational GalXC-based therapy for the treatment of chronic hepatitis B virus infection in adults. The Company anticipates human proof-of-concept data from the Phase 1 trial, which is known as DCR-HBVS-101, in the second half of 2019. DCR-HBVS is comprised of a single GalXC molecule that targets HBV messenger RNAs within the hepatitis B surface antigen gene sequence region. Preclinical studies with a standard mouse model of HBV infection showed DCR-HBVS led to greater than 99% reduction in circulating HBsAg, suggesting superior HBsAg suppression, compared to targeting within the X gene sequence region.